Respiratory infection symptoms can be misleading, and can result in misdiagnosis, unnecessary tests, overuse of antimicrobials, and the continued spread of an infection throughout the community. When you need to diagnose a respiratory infection, you shouldn’t have to choose between speed and accuracy. With the help of rapid respiratory testing solutions from Abbott, practitioners can quickly and accurately determine whether respiratory infections are self-limiting or require therapy. That can contribute to better treatment strategies, improved patient outcomes, and lower costs.
Respiratory infections pose a two-pronged threat to human health. Failure to treat patients quickly and appropriately could result in outbreaks and epidemics, while overuse of antibiotics can spur the emergence of antimicrobial-resistant infections.1, 2 Abbott's best-in-class respiratory products can help practitioners define appropriate treatment strategies fast, thus facilitating:
ID NOW Influenza A&B 2 is the world’s first-ever CLIA-waived molecular, point-of-care test.3
Rely on the market leader in rapid respiratory diagnostics.
We’re the world’s #1 maker of point-of-care (POC) infectious disease tests,4 offering an unmatched range of rapid respiratory point-of-care testing options. Our high-performance solutions help clinicians identify pathogens immediately and accurately, so they can determine appropriate treatment strategies sooner.
Based on your current location, the content on this page may not be relevant for your country.